Breaking News

Tweet TWEET

Iceland National Blood Bank Signs INTERCEPT Platelet and Plasma Agreement with Cerus

  Iceland National Blood Bank Signs INTERCEPT Platelet and Plasma Agreement
  with Cerus

Business Wire

CONCORD, Calif. -- November 20, 2013

Cerus Corporation (NASDAQ:CERS) announced today that Blóðbankinn, Iceland’s
national blood transfusion service at Landspitali University Hospital, has
signed an agreement for the purchase of the INTERCEPT Blood System for
platelets and plasma. Blóðbankinn is the sole supplier of blood components in
Iceland.

“Using INTERCEPT to help avoid the risk of transfusion transmitted infections
is our priority. The use of the INTERCEPT Blood System for platelets for the
past year has clearly demonstrated to us that such a methodology can
streamline operations, minimize associated costs and give an added value to
our organization,” says SveinnGuðmundsson, MD, PhD, Director of Blóðbankinn,
Landspitali University Hospital. “The proven clinical efficacy of INTERCEPT
pathogen inactivation to avoid bacterial contamination of platelet components
has enabled us to extend platelet shelf life from five to seven days, which
has already made our daily and weekly planning easier, increased platelet
availability for haematologic and surgical patients, and minimized outdating
of platelets. Our clinicians expect Blóðbankinn to provide them with
up-to-date services, with a focus on quality and patient safety.” Sveinn
emphasized that after a major economic crisis in 2008, the Blóðbankinn focused
on receiving added value for its investments; the adoption of INTERCEPT is an
important factor in attaining added patient safety while streamlining
operations and minimizing waste.

“We believe that the ability to replace specific procedures, such as bacterial
detection and quarantine plasma, with the INTERCEPT Blood System played a
significant part in Blóðbankinn’s decision to adopt pathogen inactivation,”
stated Caspar Hogeboom, president of Cerus Europe. “We look forward to working
with them in implementing INTERCEPT as they seek to improve blood banking
logistics and take a proactive approach to enhance blood safety for patients.”

Blóðbankinn collects 13,000 whole blood units, and processes 2,500 platelet
units and 4,000 plasma units per year, representing 100% of Iceland’s red
cell, platelet and plasma market. Blóðbankinn provides nationwide transfusion
services in Iceland, a country with a population of 320,000 people, and has a
staff of 50 people. It's emphasis on providing high quality services and focus
on patient safety enabled it to reach ISO 9001:2008 certification in the year
2000.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of
blood safety. In in vitro studies, the company’s INTERCEPT Blood System has
been demonstrated to inactivate a broad range of viruses, bacteria and
parasites that may be present in donated blood, including established threats
such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as
emerging pathogens such as influenza, malaria and dengue. Cerus currently
markets and sells the INTERCEPT Blood System for both platelets and plasma in
Europe, the Commonwealth of Independent States, the Middle East and selected
countries in other regions around the world. In the United States, Cerus is
seeking regulatory approval of the INTERCEPT Blood System for plasma and
platelets. The INTERCEPT red blood cell system is in clinical development. See
http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Except for the historical statements contained herein, this press release
contains forward-looking statements concerning Cerus’ products, prospects and
results, including statements regarding the expected impact of implementing
the INTERCEPT platelet system at the Landspitali University Hospital. Actual
results could differ materially from these forward-looking statements as a
result of certain factors, including, without limitation, risks associated
with for the implementation and use of the INTERCEPT Blood System, as well as
other risks detailed in Cerus’ filings with the Securities and Exchange
Commission, including Cerus’ Quarterly Report on Form 10-Q for the quarter
ended June 30, 2013 filed with the SEC on August 2, 2013. Cerus disclaims any
obligation or undertaking to update or revise any forward-looking statements
contained in this press release.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20131120005488/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50754651&lang=en

Contact:

Cerus Corporation
Lainie Corten, 925-288-6319
Sr Director, Global Marketing & Investor Relations